Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mina Ichiki"'
Autor:
Yuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga, Kazuki Yamaguchi, Kazuki Kato, Keiko Esaki, Kentaro Asanuma, Miho Funaki, Mina Ichiki, Yuri Ikuta, Shunsuke Ito, Eri Joyashiki, Shun-Ichiro Komatsu, Atsushi Muto, Kei Nishimura, Momoko Okuda, Hisakazu Sanada, Motohiko Sato, Norihito Shibahara, Tetsuya Wakabayashi, Koji Yamaguchi, Akiko Matsusaki, Zenjiro Sampei, Hirotake Shiraiwa, Hiroko Konishi, Yoshiki Kawabe, Kunihiro Hattori, Takehisa Kitazawa, Tomoyuki Igawa
Emicizumab, a factor (F)VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment for people with hemophilia A (PwHA). Although emicizumab is very potent, long-term outcomes from the clinical studies sugg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e05c434bee4d4affb01dcc8f26f39e
https://doi.org/10.1101/2022.12.19.520692
https://doi.org/10.1101/2022.12.19.520692
Autor:
Tetsuhiro Soeda, Motohiko Sato, Takehisa Kitazawa, Kazuki Yamaguchi, Tomoyuki Igawa, Hirotake Shiraiwa, Teranishi Yuri, Norihito Shibahara, Hidetomo Kitamura, Mina Ichiki, Hiroko Konishi, Kei Nishimura, Eri Joyashiki, Hikaru Koga
Publikováno v:
Blood. 136:19-19
Background Emicizumab (HEMLIBRA®) is a factor (F) VIII function-mimetic therapeutic bispecific antibody (BsAb) to FIXa and FX able to prevent bleeding in persons with hemophilia A (PwHA) when injected subcutaneously once every 1, 2 or 4 weeks. To de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32ef2ef4fe28d9ce9718ebc9cb713bbe
https://doi.org/10.1182/blood-2020-138958
https://doi.org/10.1182/blood-2020-138958
